<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01139203</url>
  </required_header>
  <id_info>
    <org_study_id>SH20100601</org_study_id>
    <nct_id>NCT01139203</nct_id>
  </id_info>
  <brief_title>Prophylaxis of Hepatitis B Virus Recurrence After Liver Transplantation</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <brief_summary>
    <textblock>
      Entecavir demonstrated superior virologic and biochemical benefits over lamivudine and
      adefovir. The investigators evaluated the effect of entecavir combined Hepatitis B immune
      globulin (HBIG) with lamivudine or adefovir or both combined HBIG in Chinese liver
      transplantation patients with Hepatitis B Virus (HBV) related diseases.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2009</start_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serological markers of HBV</measure>
    <time_frame>every three month after liver transplantation</time_frame>
    <description>Serological markers of HBV include HBsAg,HBsAb,HBeAg,HBeAb,HBcAb and HBV-DNA.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Liver Transplantation</condition>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>lamivudine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>lamivudine and adefovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>entecavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lamivudine adefovir entecavir HBIG</intervention_name>
    <description>lamivudine 100mg orally daily adefovir 10mg orally daily entecavir 0.5mg orally daily HBIG 2000 unit intravenously during the anhepatic phase,and followed 800 unit intramuscularly daily until day 14,then 400 unit intramuscularly twice weekly</description>
    <arm_group_label>lamivudine</arm_group_label>
    <arm_group_label>lamivudine and adefovir</arm_group_label>
    <arm_group_label>entecavir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. patients into the transplant waiting list with HBV-related liver disease.

          2. HBsAg-positive.

          3. serum HBV-DNA negative.

          4. no HCV, HDV and HIV co-infection.

          5. without renal dysfunction.

          6. No lamivudine, adefovir and entecavir drug allergy history.

          7. no HBV-YMDD mutation for patients who have a long-term use of lamivudine.

        Exclusion Criteria:

          1. patients with HBV-related hepatocellular carcinoma beyond Milan criteria.

          2. HBsAg-negative.

          3. serum HBV-DNA positive.

          4. HCV, HDV and HIV co-infection.

          5. patients with severe renal dysfunction or failure.

          6. lamivudine, adefovir and entecavir drug allergy history.

          7. HBV-YMDD mutation for patients who have a long-term use of lamivudine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhi-Hai Peng, MD PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhi-Hai Peng, MD PHD</last_name>
    <phone>0086-021-63240090</phone>
    <phone_ext>3132</phone_ext>
    <email>pengpzh@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tao Li, MD</last_name>
    <phone>0086-021-63240090</phone>
    <phone_ext>3136</phone_ext>
    <email>transplant@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai First People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhi-Hai Peng, MD PHD</last_name>
      <phone>0086-021-63240090</phone>
      <phone_ext>3132</phone_ext>
      <email>pengpzh@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Tao Li, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Patterson SJ, Angus PW. Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues. Curr Opin Organ Transplant. 2009 Jun;14(3):225-30. doi: 10.1097/MOT.0b013e32832b1f32. Review.</citation>
    <PMID>19373086</PMID>
  </reference>
  <reference>
    <citation>Angus PW, Patterson SJ. Liver transplantation for hepatitis B: what is the best hepatitis B immune globulin/antiviral regimen? Liver Transpl. 2008 Oct;14 Suppl 2:S15-22. doi: 10.1002/lt.21614. Review.</citation>
    <PMID>18825721</PMID>
  </reference>
  <reference>
    <citation>Riediger C, Berberat PO, Sauer P, Gotthardt D, Weiss KH, Mehrabi A, Merle U, Stremmel W, Encke J. Prophylaxis and treatment of recurrent viral hepatitis after liver transplantation. Nephrol Dial Transplant. 2007 Sep;22 Suppl 8:viii37-viii46. Review.</citation>
    <PMID>17890261</PMID>
  </reference>
  <reference>
    <citation>Carey I, Harrison PM. Monotherapy versus combination therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs. 2009 Nov;18(11):1655-66. doi: 10.1517/13543780903241599. Review.</citation>
    <PMID>19852566</PMID>
  </reference>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2010</study_first_submitted>
  <study_first_submitted_qc>June 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2010</study_first_posted>
  <last_update_submitted>June 25, 2010</last_update_submitted>
  <last_update_submitted_qc>June 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Shanghai First People's Hosptial</name_title>
  </responsible_party>
  <keyword>HBV recurrence</keyword>
  <keyword>entecavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

